Does dupixent cause asthma?

Does Dupixent cause asthma?

Dupixent does not cause asthma. It is an approved treatment for certain types of asthma.

Why do people ask if Dupixent causes asthma?

Dupixent treats moderate-to-severe asthma driven by type 2 inflammation. Patients or caregivers may see the drug listed for asthma and wonder whether it triggers the condition rather than controls it.

How does Dupixent work in asthma?

Dupixent blocks interleukin-4 and interleukin-13 signaling. These cytokines drive the airway inflammation that produces asthma symptoms. By interrupting that pathway, the drug reduces exacerbations and improves lung function in eligible patients.

What clinical data support its use in asthma?

Three phase 3 trials showed Dupixent lowered annualized asthma exacerbation rates by 46-67 percent compared with placebo in patients with uncontrolled moderate-to-severe asthma and elevated eosinophils or fractional exhaled nitric oxide. Improvements appeared within two weeks and persisted through 52 weeks [1].

When is Dupixent prescribed for asthma?

The FDA approved Dupixent as an add-on maintenance treatment for patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or oral-corticosteroid dependence. It is not indicated for acute bronchospasm or status asthmaticus.

Can Dupixent worsen asthma symptoms?

In the pivotal trials, asthma worsening was reported at rates similar to or lower than placebo. Injection-site reactions, conjunctivitis, and herpes infections were the most common adverse events. Abrupt discontinuation can lead to return of symptoms, but this reflects loss of disease control rather than a new asthma trigger.

What happens if someone without asthma takes Dupixent?

Dupixent is not approved for people without an indicated inflammatory condition. Limited data exist on use in healthy individuals; any off-label exposure would be outside established safety parameters.

How does Dupixent compare with other asthma biologics?

Dupixent targets IL-4/IL-13, while Nucala, Fasenra, and Cinqair block IL-5 or its receptor. Choice depends on biomarker profile, dosing frequency, and comorbid conditions such as atopic dermatitis or chronic rhinosinusitis with nasal polyps.

When does the Dupixent patent expire?

The composition-of-matter patent listed in the FDA Orange Book expires in 2031, with additional method-of-use and formulation patents extending protection potentially into the mid-2030s. Biosimilar or interchangeable versions are unlikely before these dates lapse [2].

DrugPatentWatch.com tracks these patent and exclusivity timelines for Dupixent and competing biologics.

[1] Castro M, et al. N Engl J Med. 2018;378:2486-2496.
[2] DrugPatentWatch.com – Dupixent patent and exclusivity data.